Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG

This trial was a prospective, multicenter, and self controlled clinical trial. The subjects who were in line with this scheme were detected by fluorimetry and staining, and the primary effectiveness evaluation index, secondary effectiveness evaluation index and safety evaluation index were established during the operation. Record evaluation. At present, in the clinic for sentinel lymph node biopsy of breast cancer, routine medical treatment is a blue staining method. A large number of clinical data show that the number of blue staining methods was 1-2.4, and the number of fluorescence detection is 2-3.7. Therefore, choosing a self controlled clinical trial can increase the number of sentinel lymph node detection.

Inclusion criteria

• the age of 18-75 years, female patients;
• the diagnosis of breast cancer by biopsy;
• participants voluntarily participated in the clinical trial and signed informed consent.

Exclusion criteria

• had received SLNB or axillary surgery;
• breast area radiotherapy or neoadjuvant chemotherapy has been accepted.
• clinical hints of axillary lymph node metastasis;
• discovery of distant metastasis;
• inflammatory breast cancer;
• women in pregnancy;
• people with iodine allergy;
• the serum creatinine was > 1.5 times as high as the upper limit of the normal value.
• to participate in clinical trials of other devices or drugs within one month;
• the researchers consider it inappropriate to participate in this clinical trial.